BOSTON SCIENTIFIC CORP (BSX)
US1011371077 - Common Stock
Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 187 industry peers in the Health Care Equipment & Supplies industry. While BSX has a great profitability rating, there are some minor concerns on its financial health. BSX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year BSX was profitable.
BSX had a positive operating cash flow in the past year.
Of the past 5 years BSX 4 years were profitable.
Each year in the past 5 years BSX had a positive operating cash flow.
1.2 Ratios
BSX's Return On Assets of 4.93% is amongst the best of the industry. BSX outperforms 83.87% of its industry peers.
With an excellent Return On Equity value of 8.98%, BSX belongs to the best of the industry, outperforming 83.87% of the companies in the same industry.
With an excellent Return On Invested Capital value of 6.13%, BSX belongs to the best of the industry, outperforming 82.26% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 8.19%.
The 3 year average ROIC (5.38%) for BSX is below the current ROIC(6.13%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.93% | ||
| ROE | 8.98% | ||
| ROIC | 6.13% |
ROA(3y)3.17%
ROA(5y)4.9%
ROE(3y)5.91%
ROE(5y)10.17%
ROIC(3y)5.38%
ROIC(5y)4.7%
1.3 Margins
The Profit Margin of BSX (12.01%) is better than 87.63% of its industry peers.
In the last couple of years the Profit Margin of BSX has declined.
BSX has a better Operating Margin (17.95%) than 90.32% of its industry peers.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
BSX has a Gross Margin of 69.08%. This is amongst the best in the industry. BSX outperforms 80.65% of its industry peers.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.95% | ||
| PM (TTM) | 12.01% | ||
| GM | 69.08% |
OM growth 3Y23.29%
OM growth 5Y-0.75%
PM growth 3YN/A
PM growth 5Y-8.31%
GM growth 3Y2.2%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
Compared to 1 year ago, BSX has more shares outstanding
BSX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BSX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.42 indicates that BSX is not in any danger for bankruptcy at the moment.
BSX's Altman-Z score of 5.42 is fine compared to the rest of the industry. BSX outperforms 78.49% of its industry peers.
BSX has a debt to FCF ratio of 5.74. This is a neutral value as BSX would need 5.74 years to pay back of all of its debts.
BSX has a Debt to FCF ratio of 5.74. This is in the better half of the industry: BSX outperforms 79.03% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that BSX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.44, BSX is doing worse than 60.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 5.42 |
ROIC/WACC0.73
WACC8.43%
2.3 Liquidity
BSX has a Current Ratio of 1.61. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BSX (1.61) is worse than 80.11% of its industry peers.
A Quick Ratio of 1.14 indicates that BSX should not have too much problems paying its short term obligations.
BSX's Quick ratio of 1.14 is on the low side compared to the rest of the industry. BSX is outperformed by 75.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.15% over the past year.
The Earnings Per Share has been growing slightly by 6.73% on average over the past years.
BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.64%.
The Revenue has been growing slightly by 7.71% on average over the past years.
EPS 1Y (TTM)16.15%
EPS 3Y28.77%
EPS 5Y6.73%
EPS Q2Q%16.98%
Revenue 1Y (TTM)13.64%
Revenue growth 3Y12.83%
Revenue growth 5Y7.71%
Sales Q2Q%14.48%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.88% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 9.85% on average per year.
EPS Next Y18.53%
EPS Next 2Y16.01%
EPS Next 3Y14.86%
EPS Next 5Y12.88%
Revenue Next Year15.36%
Revenue Next 2Y13.09%
Revenue Next 3Y12.05%
Revenue Next 5Y9.85%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 39.17, BSX can be considered very expensive at the moment.
72.58% of the companies in the same industry are more expensive than BSX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 31.52. BSX is valued slightly more expensive when compared to this.
BSX is valuated quite expensively with a Price/Forward Earnings ratio of 31.66.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 74.73% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.55. BSX is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.17 | ||
| Fwd PE | 31.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit cheaper than the industry average as 68.28% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BSX is valued a bit cheaper than 73.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.83 | ||
| EV/EBITDA | 34.31 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of BSX may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 14.86% in the coming years.
PEG (NY)2.11
PEG (5Y)5.82
EPS Next 2Y16.01%
EPS Next 3Y14.86%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BOSTON SCIENTIFIC CORP
NYSE:BSX (10/14/2024, 3:05:05 PM)
87.345
+0.25 (+0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap128.63B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.17 | ||
| Fwd PE | 31.66 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.11
PEG (5Y)5.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.93% | ||
| ROE | 8.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 17.95% | ||
| PM (TTM) | 12.01% | ||
| GM | 69.08% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)16.15%
EPS 3Y28.77%
EPS 5Y
EPS Q2Q%
EPS Next Y18.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.64%
Revenue growth 3Y12.83%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y